18F-Pentixafor PET in Hematologic Malignancies
NCT07122674 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-08-14
Summary
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
Conditions
Interventions
- DRUG
-
18F-Pentixafor
Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
Sponsors & Collaborators
-
First Affiliated Hospital of Zhejiang University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
Countries
- China
Study Locations
More Related Trials
-
Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor
NCT03721055 ·Status: UNKNOWN ·Phase: NA
-
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
NCT06813742 ·Status: RECRUITING
-
Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma
NCT04747561 ·Status: UNKNOWN ·Phase: NA
-
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
NCT05255926 ·Status: RECRUITING ·Phase: NA
-
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
NCT04504526 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807 ·Status: RECRUITING
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis
NCT03033485 ·Status: UNKNOWN ·Phase: NA
-
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NCT05662540 ·Status: RECRUITING ·Phase: NA
-
PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia
NCT05919199 ·Status: UNKNOWN
-
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
NCT03436342 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN
-
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 ·Status: RECRUITING
-
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
NCT05448404 ·Status: UNKNOWN ·Phase: NA
-
18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
NCT05983796 ·Status: UNKNOWN ·Phase: NA
-
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
NCT02441972 ·Status: UNKNOWN ·Phase: PHASE1
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING
-
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
NCT04992156 ·Status: COMPLETED
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma
NCT03973164 ·Status: COMPLETED
-
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
NCT03511768 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
[18F]FPIA PET/CT Imaging in Patients With Solid Tumours
NCT04717674 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277 ·Status: NOT_YET_RECRUITING